UPDATE: Wedbush Initiates Epizyme on Highly Meaningful Therapeutics Targeting HMTs

In a report published on Wednesday, Wedbush analyst Gregory R. Wade initiated coverage on

with an Outperform rating and a $37 price target. In the report, Wedbush stated, "Advances in genetically defining sub-sets of cancer patients have identified members of the family of histone methyltransferase (HMT) proteins as key drivers of malignancy. EPZM's small molecule drug discovery platform seeks to marry the appropriate HMT antagonist with the genetically definable malignancy." Epizyme closed on Wednesday at $26.96.